BioCapTM ISL1 mRNA
Catalog Number: 1003701| SKU | Price | Buy |
|---|---|---|
| 1003701-500ug | $1,550.00 | |
| 1003701-1mg | $2,025.00 |
Description
ISL1
SPECIES:
Human
ENCODED PROTEIN NAME:
Insulin gene enhancer protein ISL-1
Function:
DNA-binding transcriptional activator. Recognizes and binds to the consensus octamer binding site 5'-ATAATTAA-3' in promoter of target genes. Plays a fundamental role in the gene regulatory network essential for retinal ganglion cell (RGC) differentiation. Cooperates with the transcription factor POU4F2 to achieve maximal levels of expression of RGC target genes and RGC fate specification in the developing retina. Involved in the specification of motor neurons in cooperation with LHX3 and LDB1. Binds to insulin gene enhancer sequences. Essential for heart development. Marker of one progenitor cell population that give rise to the outflow tract, right ventricle, a subset of left ventricular cells, and a large number of atrial cells as well, its function is required for these progenitors to contribute to the heart. Controls the expression of FGF and BMP growth factors in this cell population and is required for proliferation and survival of cells within pharyngeal foregut endoderm and adjacent splanchnic mesoderm as well as for migration of cardiac progenitors into the heart (By similarity). (Source: UniProt http://www.uniprot.org/uniprot/p61371)
Sequence (349 aa):
For the DNA coding sequence that is used as the template to synthesize the ISL1 mRNA mimetic, please contact us at customerservice@pharna.com.
For potential mRNA mimetics encoding splice variants or isoforms of your interest, please contact us at customerservice@pharna.com and it is our promise to fulfill your needs.
PhaRNA, LLC is looking for academic and industry collaborators and partners to co-develop RNA-based therapeutics including vaccines for the prevention or treatment of microbial diseases caused by parasites, fungi, viruses and bacteria. Our company’s proprietary technology has the versatility of rapidly designing RNA-based products for testing and development in preclinical and clinical settings. More specifically, we are looking for potential collaborators and partners who have the capacity to take our custom-designed RNA products and test their efficacy using molecular, cell biological and animal models. We will then partner to develop the most promising drug candidates through early phase clinical studies. We believe that this form of collaboration will capitalize on the strengths of PhaRNA, LLC and the partnering organization to rapidly test and develop potentially life-saving drugs and vaccines. Interested parties, please contact us directly.